Silvia Novello

Feb 29, 2024 | thelancet.com | Umberto Malapelle |Silvia Novello

In the era of precision oncology, a rapidly increasing number of predictive biomarkers have been routinely implemented to define the advanced non-small cell lung cancer (NSCLC) patients’ treatment decision making process.

Feb 6, 2023 | thelancet.com | Francesco Passiglia |Silvia Novello

In this issue of eClinicalMedicine, Ou and colleagues published the results of the CORIN (GASTO1003), phase II, randomised trial, comparing adjuvant therapy with first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), icotinib, versus clinical observation in 128 patients with surgically resected, EGFR-mutant, stage IB (7th TNM edition) non-small cell lung cancer (NSCLC) without adjuvant chemotherapy. 1Ou W. Li N. Wang B.-X. et al.